{
  "id": 19720865,
  "title": "Earnings call transcript: Lineage Cell rises on Q3 2026 pipeline update",
  "url": "https://urgent.news/2026/11/12/earnings-call-transcript-lineage-cell-rises-on-q3-2026-pipeline-update",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-12T22:52:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-lineage-cell-rises-on-q3-2026-pipeline-update-93CH-5023602"
  },
  "original_language": "en",
  "account": "Lineage Cell Therapeutics reported a sharp decline in Q3 2026 revenue, falling to $1.5 million from $3.7 million the previous year. The company's net income improved to $4.2 million, or $0.02 per share, after a $28 million loss in the same period last year. This profit improvement was primarily due to a non-cash warrant remeasurement tied to a lower share price, rather than stronger operational performance. The company's cash position is strong, with $45.2 million in cash, equivalents and marketable securities as of September 30, 2026, providing a runway into Q2 2028. Lineage has expanded its pipeline, adding three new allogeneic cell transplant campaigns: OpRegen, OPC1 and HUNT1. The HUNT1 Huntington's disease program was acquired from NeuroAirmid Therapeutics, immediately expanding the company's clinical portfolio. Despite the improved metrics, the company's operating expenses rose 17.3% to $8.8 million, and research and general administrative costs increased 16.7% to $4.9 million. No earnings forecast was provided alongside the quarterly results, making it difficult to measure the results against published revenue or EPS targets. The stock was recently quoted at $0.805, up 1.9% from the previous close of $0.79, indicating investor caution and a modest reaction to the update.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}